[The study of the expression, effect and clinical relationship of TGF-beta1 CD44V6 bcl-2 and p53 in the larynx squamous carcinoma].
This study was to measure the expression of TGF-beta1 in larynx squamous carcinoma, to investigate the relationship between TGF-beta1 and the expressions of CD44V5 , bcl-2 and p53, and the relationship between TGF-beta1 and pathological grading of tumours, the clinical staging and the survival rate of the patients, through which the effect of TGF-beta1 on the pathogenesis of the larynx squamous carcinoma was to be known. With immunohistochemistry, the expressions of TGF-beta1, CD44V6, bcl-2 and p53 were measured in the paraffin sections of the larynx squamous carcinoma tissues of 43 patients. In pathological grading I, II, III, respectively, the positive expression ratios of TGF-beta1 were 86.96%, 82.35%, 100.00%; CD44V6 were 60.87%, 70.59%, 100.00%; bcl-2 were 82.61%, 94.12%, 100.00%; p53 were 26.09%, 35.29%, 66.67%. (1) TGF-beta1 had some relationships to the pathological grading, the clinical staging, the metastasis to cervical lymph node, the survival rates of patients in 3 and 5 years. TGF-beta1 can be used as a marker to evaluate the development and predict the metastasis of tumors and the prognosis of patients. (2) The expression of TGF-beta1 in larynx carcinoma had some correlation to CD44V6, bcl-2 and p53.